Wednesday, August 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 24, 2026

Is HP (HPQ) Still Attractive After Recent 27% Monthly Share Price Jump?

View original at finance.yahoo.com
Is HP (HPQ) Still Attractive After Recent 27% Monthly Share Price Jump? Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • HP scores a 5 out of 6 valuation score, indicating it screens as undervalued on most standard checks

    60% confidence
  • HP's 1-year return of -5.2% is lagging behind its peers

    60% confidence
  • HP's DCF-derived intrinsic value is $44.87 per share, implying the stock trades at a 43.8% discount to fair value at approximately $25.24

    60% confidence
  • 49 additional high-quality undervalued stocks are identified by Simply Wall St's screening methodology alongside HP

    60% confidence
  • HP's DCF model uses a 2 Stage Free Cash Flow to Equity approach; analyst and extrapolated estimates suggest free cash flow of approximately $2.77b in 2026, rising to approximately $3.28b by 2035

    60% confidence

Data points we hold from this source

HP Inc. · cash2.77 USD
HP Inc. · stock price21.3 percent_7d_return
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com